Incidence and clinical feature of hypocalcemia after parathyroidectomy in primary hyperparathyroidism patients / 国际外科学杂志

Objective To analyze and discussed the incidence and clinical feature of the hypocalcemia after parathyroidectomy in patient with primary hyperparathyroidism.Methods Thirty seven patients with primary hyperparathyroidism who were hospitalized at the Department of General Surgery,Second Affiliated Hospital of China Medical University from Jan 2012 to Sep.2016,their clinical data were analyzed retrospectively.Divided in 4 groups by symton,count the incidence of hypocalcemia of each group and hospital stay after operation,analyze and compare the difference of each group,summarize its regularity.SPSS20.0 statistical software was adopted.The results of metering data were indicated by mean and standard deviation,and Kruskal-Wallis group was used to compare the rank.When the sample size was less than 40,the Fisher exact probability method was used for the test,and when the sample size was large,chi-square test was adopted.Results Postoperative hypocalcemia occured in 26 patients in total,the incidence was 70.2％,the average length of hospital stay after parathyroidectomy was 7.2 days;postoperative hypocalcemia occured in 7 patients in bone type group patients,the incidence was 87.5％,the average length of hospital stay after parathyroidectomy was 11.6 days;postoperative hypocalcemia occured in 6 patients in renal type group patients,the incidence was 46.1％,the average length of hospital stay after parathyroidectomy was 5.5 days;postoperative hypocalcemia occured in 10 patients in asymptomatic type group patients,the incidence was 76.9％,the average length of hospital stay after parathyroidectomy was 4.8 days.Mixed type group,digestive system type group and neuropsychiatric type group has 1 patients respectively,and postoperative hypocalcemia occured in all of them.There was statistically significant difference in the incidence of hypocalcemia among bone type group,renal type group and asymptomatic type group (P =0.147),and there was significant difference in the postoperative hospitalization days among groups (x2 =11.202,P =0.004).Conclusions Hypocalcemia is a commom complication after parathyroidectomy in patients with primary hyperparathyroidism.The incidence of hypocalcemia was highest in bone type group,and it has the longest length of hospital stay,so surgeons should be alert to the occurrence of hypocalcemia in bone type patients most.The severity of hypocalcemia on renal and asymptomatic type patients is lower,they can be discharged from the hospital at discretion as early as possible.

Core needle biopsy for molecular classification of breast cancer / 中华普通外科杂志

Objective To evaluate core needle biopsy (CNB) in detecting estrogen receptor (ER) and progesterone receptor (PR) of HER2,Ki67,and molecular classification of breast cancer.Methods Clinical data of 188 breast cancer patients admitted from Nov 2012 to Jun 2015,were retrospectively analyzed.All patients received both CNB and open excision biopsy (OEB).Immunohistochemistry (IHC) was used to evaluate the expression of ER,PR,HER2 and Ki67.All cases were categorized into four molecular subtypes:Luminal A,Luminal B,triple negative breast canccr and HER2 over-expression breast cancer.Kappa test was used to evaluate the consistency of CNB and OEB.Results Concordance rate of ER,PR,HER2 receptor status and Ki67 value were 94.68％,93.62％,94.68％ and 73.40％.There was no difference between CNB and OEB for non-Luminal tumors (P =0.774).Ki67 expression in OEB samples was higher than in CNB samples (25.90％ vs.21.65％,P ＜ 0.001).Concordance rate between CNB and OEB for molecular subtypes was 72.34％ (K =0.606 4).Conclusions CNB is accurate in evaluating ER,PR,HER2 and Ki67 in breast cancer.CNB is accurate in diagnosing non-Luminal molecular subtypes of breast cancer.

Clinicopathologic analyses of Castleman′s disease and review of the literature / 临床与实验病理学杂志

Purpose To describe clinicopathological features, diagnosis and differential diagnosis of Castleman′s disease. Methods Retrospective analyses of the clinical data, clinicopathology and immunohistochemistry were conducted in ten cases of Castleman dis-ease and reviewed of literature. Results There were 8 cases of unicenrtic Castleman′s disease and 2 cases of multicentric Castleman′s disease. Pathologically, there were 6 cases of hayline vascular types, one case of plasmatcyic type and 3 cases of mixed type in all Castleman′s disease. Immunohistochemically, all cases were negative for BCL-6 and CD10, and Ki-67 expression was less than or e-qual to 30%. There were 4 cases with complete follow-up data, including one case of intermediate type, 3 cases of hyaline vascular type which were healed by surgical resection without recurrence. Conclusions Castleman′s disease is a rare and lymphoproliferative disorders with unknown cause, it is not easy to diagnose before the operation. Whether immunohistochemical features reflect abnormal immune function or play unknown role in the pathogenesis of Castleman′s disease is also demanded further study.

Influences of pancreatic cancer cell PANC-1 proliferation of downregulating Berlin1 expression / 中国综合临床

Objective To observe the influences of Bcl-2 expression and pancreatic cancer cell proliferation after downregulating Beclin1 expression and discuss the mechanism.Methods Target interfering plasmid siBeclin1 was constructed and transfected to PANC-1 cell,and cells were divided into non transfected group(Beclin1 group),blank control group(control siNegative group) and transfection group(siBeclin1 group).Western blot and qRT-PCR were used to detect the transfection efficiency and Bcl-2 expression after transfection.Proliferation was detected by MTT.Results Western blot and qRT-PCR results showed that expression of Beclin1 in siBeclin1 group was lower than Beclin1 and siNegative control groups (27.823± 1.432,8.635±1.481,26.904±1.098;F=8.176,P＜0.01),qRT-PCR showed that the Beclin1 mRNA level of PANC-1 cells in siBeclin1 group was lower than Belcin1 and siNegative groups (0.421 ±0.157,0.194±0.104,0.399 ±0.123;F=5.239,P＜0.01),and the silencing rate was about 60％-70％.Bcl-2 protein expression and levels of mRNA in siBeclin1 group were significantly higher than that of Beclin1 group(26.912±1.927,8.004±1.534,t =7.329,P＜0.01;0.582±0.297,0.217±0.186,t =6.835,P＜0.01);MTT results showed that the proliferation of PANC-1 cells were strengthened,(61.54±6.81)％ and (46.78±7.28)％ at 72 h,(76.39±7.26)％ and (54.27±8.17)％ at 96 h,and the difference was significant(t=3.674,P＜0.05;t =10.185,P ＜0.01).Conclusion Proliferation of pancreatic cancer cells are strengthened after Beclin1 expression downregulating,so Beclin1 may inhibit the proliferation of pancreatic cancer cells by Bcl-2 downregulating.Beclin1 can be a target candidate gene of pancreatic cancer therapy.